GHP Healthcare and Pharmaceutical Awards 2026 the industry will require clear, practical regulatory guidance. Until then, organisations must approach adoption carefully, balancing innovation with compliance.” With such deep sectoral expertise and a strong understanding of its clients’ needs, Smiro Qualitas has positioned itself as a trusted partner capable of guiding organisations through this complex landscape. The company has solidified this position through obtaining its MIA, MIA(IMP), and WDA(H) licences, which have also provided the team with a strong foundation for scaling the business. Smiro Qualitas has further cemented itself as a key player in the pharmaceutical industry through the establishment of its site in Malta, allowing the company to provide a fully integrated service offering across both the UK and the EU. “This was a deliberate and strategic decision,” Robert told us. “We wanted to be pioneers. To our knowledge, our facility is the first of its kind in Malta, and we are proud to contribute to both the local clinical landscape and our clients’ ability to access the EU market.” Recently, Smiro Qualitas has supported a company entering the UK market in successfully securing its MIA and MDA(H) licences, which allow the client company to import, certify, release, and distribute its products in the market. To date, Smiro Qualitas has supported the success of 122 clinical studies, and lending its superlative services to 108 clients and driving the pharmaceutical industry forward. Smiro Qualitas was founded in 2012, beginning as a one-person venture established by experienced Pharmacist and Qualified Person Robert Smith. The company has since grown into an independent consultancy driven by a dedicated team of seven permanent professionals boasting more than 120 years of combined industry experience across all major sectors. Robert has led his team from strength to strength, raising Smiro Qualitas to stand as the UK’s Best Independent Pharmaceutical Industry Consultancy 2026. “For me, running Smiro Qualitas is not just a profession; it is a vocation,” he shared. “Since the age of 14, when I first understood how medicines can transform patients’ lives, this has been my driving passion. From my early career as a hospital pharmacist to becoming a Qualified Person in industry and now leading a group of companies, my focus has remained the same: ensuring patients have access to safe, effective, high-quality medicines. Everything we do at Smiro Qualitas ultimately comes back to that purpose.” As Smiro Qualitas continues to grow, a key priority for the team is maintaining and strengthening its customer focus. The company understands that what worked as a small organisation is not sustainable at scale, and is proactively evolving its structure to support both its clients and its people. It is currently undergoing a management restructuring to ensure clear accountability across operations, while allowing for greater strategic oversight at director level. It has also introduced a dedicated client liaison function to ensure seamless onboarding, maintaining the calibre of consistent delivery that has earned it the GHP Client Satisfaction Excellence Award 2026. 2026 is shaping up to be another strong year of growth and development for Smiro Qualitas, with new clients already onboarded and further opportunities in the pipeline. As the company explores expansion into additional healthcare services to broaden its offerings, we at Global Health & Pharma have no doubt that Smiro Qualitas will continue to lead the way in today’s pharmaceutical sphere. Contact: Robert Smith Company: Smiro Qualitas Web Address: www.smiroqualitas.co.uk
RkJQdWJsaXNoZXIy MTUyMDQwMA==